The present disclosure relates to a chemiluminescent substrate solution and a chemiluminescence detection method. The chemiluminescent substrate solution includes a chemiluminescent substrate, a fluorescein, and a water-soluble polymeric quaternary ammonium salt, wherein the chemiluminescent substrate is selected from chlorinated dioxetane compounds with a spiroadamantane substituent. The chemiluminescent substrate solution has a wider linear detection range.

Apparatus and methods are described for use with a bodily emission of a subject and a toilet bowl containing water. A plurality of molecules are disposed on a substrate, each of the molecules comprising an epitope that is configured to target a biomarker and a color reporter molecule conjugated to the epitope. The color reporter molecule is configured to undergo a color change from a first color to a second color in response to being in reactive proximity with the biomarker within the water within the toilet bowl. Other applications are also described.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

The present invention provides assay devices and methods for detecting the presence of an analyte in a sample. Devices according to the invention include a reagent zone, one or more capture zones and a detection zone. Capture zones can reduce the quantity of labelled conjugate that reaches the detection zone in the presence of a negative marker in the sample and/or in the absence of a positive marker in the sample, facilitating high sensitivity and improved specificity testing.

The present invention relates to a vegan immunoassay for detecting a biologically active antigen, a device in which such an immunoassay is arranged, a kit comprising such a device as well as the use of the immunoassay and a method for detecting a biologically active antigen.

The present invention describes a whole blood assay chip that enables separation of the cellular compartment from surrounding plasma, facilitating multiplexed measurement of otherwise difficult to detect soluble factors produced upon cellular stimulation. The invention is a microfluidic chip with an incubation chamber comprising an inlet, an outlet, and a fluidic barrier. Using this platform, the cellular compartment can be stimulated with various substances and levels of immunologic biomarkers could be measured. Through a proprietary immunologic algorithm described herein, this would allow for the diagnosis of an allergic response to foods, antibiotics, and/or other drugs. Additional applications of the invention besides allergy testing could include pregnancy testing, blood type, and medical applications requiring whole blood cellular stimulation readouts.

Provided herein are methods for detecting or predicting a disease or condition related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) by obtaining or having obtained a biological sample from a subject; and determining the LH/FSH ratio in the biological sample, wherein a decrease in the LH/FSH ratio when compared to an age-matched subject that does not have a disease or condition of LH/FSH is indicative of a current or future disease or condition of LH/FSH.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

This invention relates to aptamers having selectivity and/or specificity for human chorionic gonadotropin (hCG). Also provided for are a biosensor comprising the aptamers having selectivity and/or specificity for hCG and a method for detecting human chorionic gonadotropin (hCG) in a sample using the aptamers or biosensor of the invention, comprising detecting binding of the aptamers to hCG. The invention also relates to a method of identifying aptamers, from a candidate mixture of nucleic acids, that bind to a distinct site of a target molecule, as opposed to another site on the target molecule.

Disclosed herein is a system for the quantification of low-concentration analytes in a sample, such as culture of human embryos. The system allows for the accurate identification and quantification of an analyte, for example a protein, at a resolution and sensitivity less than 1 pg/ml. The disclosed system provides a non-invasive, rapid, and precise measurement platform, thereby enabling better patient care through more informed medical decision-making. Also disclosed herein is a method for using the disclosed system for quantifying analytes in a sample.